01715nas a2200301   4500000000100000008004100001260001600042653002300058653002100081653001200102653002000114653001200134653002000146653001500166653001700181653001700198653001700215653001500232100001600247700001500263700001400278700001400292245009500306300001200401490000600413520098000419022001401399       1964                            d  c1964 Nov 2810aAntibody Formation10aCyclophosphamide10aDapsone10aImmunochemistry10aleprosy10aLeukocyte Count10aLeukopenia10aPharmacology10aSouth Africa10aStreptomycin10atoxicology1 aDavison A R1 aSchulz E J1 aFalkson G1 aEgnal M L00aEffect of Cyclophosphamide on Leprosy. Competitive Action of Cyclophosphamide and Dapsone.  a1138-410 v23 a<p>Cyclophosphamide is a propylene phosphoric ester diamide which is used in the treatment of neoplasms, though it is limited by the development of leucopenia. One of the authors (G. Falkson), in 1960, saw a leprosy patient who had been given Cyclophosphamide because of mistaken diagnosis of mycosis fungoides. The dermal infiltration and the neuritic symptoms of the leprosy patient had diminished with treatment. Accordingly 8 Bantu patients, at Westfort Institution, Pretoria, were given Cyclophosphamide intravenously in doses varying from 400 to 800 mgm. daily, followed, in 4 patients, by 100 mgm. daily by mouth. In 4 patients who received dapsone together with Cyclophosphamide, the leucopenic effect of the latter was inhibited. There was 1 patient with lepromatous leprosy who received only Cyclophosphamide for a long time; he benefited considerably. There is evidence that Cyclophosphamide may inhibit acute reactions in leprosy. The results are tabulated.</p>
  a0140-6736